187 related articles for article (PubMed ID: 12736022)
1. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
Noguchi M; Yahara J; Noda S
Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
3. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
4. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
[TBL] [Abstract][Full Text] [Related]
7. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer.
Koga H; Naito S; Koto S; Sakamoto N; Nakashima M; Yamasaki T; Noma H; Kumazawa J
Prostate; 1999 Apr; 39(1):1-7. PubMed ID: 10221259
[TBL] [Abstract][Full Text] [Related]
8. Collagen derived serum markers in carcinoma of the prostate.
Rudnicki M; Jensen LT; Iversen P
Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
[TBL] [Abstract][Full Text] [Related]
9. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
[TBL] [Abstract][Full Text] [Related]
10. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
Zissimopoulos A; Bantis A; Stellos K; Petrakis G; Matthaios D
J BUON; 2008; 13(1):69-74. PubMed ID: 18404790
[TBL] [Abstract][Full Text] [Related]
11. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.
Akimoto S; Okumura A; Fuse H
Endocr J; 1998 Apr; 45(2):183-9. PubMed ID: 9700471
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma.
Hosoya Y; Arai K; Honda M; Sumi S; Yoshida K
Eur Urol; 1997; 31(2):220-3. PubMed ID: 9076470
[TBL] [Abstract][Full Text] [Related]
13. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
Akimoto S; Furuya Y; Akakura K; Ito H
Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
[TBL] [Abstract][Full Text] [Related]
14. Serum carboxy-terminal cross-linked telopeptide of type I collagen reflects bone metastasis in hepatocellular carcinoma.
Ueno T; Hashimoto O; Sugawara H; Ogata R; Kusaba N; Torimura T; Sata M; Tanikawa K
Int J Oncol; 1998 Aug; 13(2):297-303. PubMed ID: 9664125
[TBL] [Abstract][Full Text] [Related]
15. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
[TBL] [Abstract][Full Text] [Related]
16. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
Kobayashi Y; Tokue A
Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
[TBL] [Abstract][Full Text] [Related]
17. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
18. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
Igawa T; Sakai H; Kanetake H; Saito Y
Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
[TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
20. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
